Centessa Pharmaceuticals のニュースと活動

Centessa Pharmaceuticals を含む合併、買収、資金調達。

• Eli Lilly has announced the acquisition of Centessa Pharmaceuticals  (2026年3月31日に公開).

34人の主要幹部と一緒に組織図を見る

Centessa Pharmaceuticalsでもっとも検索された略歴

• Mario Alberto Accardi, Chief Executive Officer
• Francesco De Rubertis, Chairman of The Board
• Mary Lynne Hedley, Director

更新履歴 - ％sの

• Chief Executive Officer and DirectorのSaurabh Sahaは20261月1 に退社予定 (2025年12月11日公開されたニュース).
• President of Orexin Programだった Mario Accardiは20261月1にChief Executive Officerに昇格予定 (2025年12月11日公開されたニュース).

アラートを作成
Centessa Pharmaceuticals のエグゼクティブの異動をフォローします。

Centessa PharmaceuticalsはSanofi (フランス共和国),Eli Lilly (アメリカ合衆国（米国）),Moderna (アメリカ合衆国（米国）)を含む1,913の競合企業を有します。

Popular M&A news in 医薬品

• Corden Pharma has announced the acquisition of AmbioPharm  (2026年6月5日に公開).
• Laboratoire Servier has announced the acquisition of Edgewise Therapeutics  (2026年6月4日に公開).
• ％sは、％s百万ドルの資金調達を発表しました。 (2026年6月3日に公開).

医薬品業界でのその他のコンタクトの提案

• Johnson & Johnson 社 Joaquin Duato - Chief Executive Officer and Chairman of the Board
• Abbott 社 Robert Ford - Chief Executive Officer and Chairman of the Board
• Sandoz 社 Richard Saynor - Chief Executive Officer

医薬品業界についてさらに知る

％sによる最新のプレスリリース

• Centessa Pharmaceuticals Announces Addition of Harris L. Rotman, PhD, as Senior Vice President of Regulatory Affairs | Centessa Pharmaceuticals
• Centessa Pharmaceuticals Announces Appointment of Dr. Mathias Hukkelhoven to its Board of Directors | Centessa Pharmaceuticals
• Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences | Centessa Pharmaceuticals
• Centessa Pharmaceuticals Announces Poster Presentation of First Preclinical Data for LockBody® Program at 2022 ASCO Annual Meeting | Centessa Pharmaceuticals
• Centessa Pharmaceuticals Makes Strategic Decision to Discontinue Clinical Development of Lixivaptan for Autosomal Dominant Polycystic Kidney Disease (ADPKD) | Centessa Pharmaceuticals
• Centessa Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Updates | Centessa Pharmaceuticals
• Centessa Pharmaceuticals Doses First Subject in Global Phase 3 ACTION Study of Lixivaptan in Autosomal Dominant Polycystic Kidney Disease | Centessa Pharmaceuticals
• Centessa Pharmaceuticals Reports Fourth Quarter and 2021 Financial Results and Provides Business Update | Centessa Pharmaceuticals
• Centessa Pharmaceuticals Expands Management Team and Adds to Extensive Development Expertise | Centessa Pharmaceuticals
• Centessa Pharmaceuticals to Present at the Guggenheim Genomic Medicines & Rare Disease Day | Centessa Pharmaceuticals
• View more press releases Close

％sについてのソーシャルメディア

• Centessa Pharmaceuticals についてのウィキペディア,Google News & Yahoo Financeの記事
• Centessa Pharmaceuticals についてのLinkedIn,ツイッター & YouTubeの記事